Companies
Scholar Rock wins FDA approval for ISEMBYLD, first muscle-targeted SMA treatment
The approval covers adults and children ages 2 and older already receiving SMN2-targeted treatment. Scholar Rock says its U.S. launch is underway, with shipments expected in the coming days.